Estrogen-calcium interactions in the postmenopause

a quantitative description

Robert P. Heaney

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Accumulated data describing the time course of bone loss in postmenopausal women were combined with metabolic data on estrogen-calcium interactions to produce a comprehensive, quantitative model of involutional bone loss. The model was shown to be able to mimic results of published intervention studies with considerable fidelity. Implicit in existing understanding, and made explicit by the model, are such relationships as: (1) calcium deficiency, if present in a woman, is masked during the early years of estrogen withdrawal bone loss; (2) accordingly, except in severe deficiency states, it is unlikely that calcium supplementation can confer much benefit in the immediate postmenopause; (3) however, by 5-8 years postmenopause, an underlying calcium deficiency, if present, becomes manifest, and if uncorrected will greatly augment the bone loss produced by estrogen withdrawal; (4) estrogen replacement therapy, if stopped, does not produce a sustained difference in bone mass in calcium-replete women; however, (5) estrogen, by effectively reducing the level of any calcium deficiency that may be present, does produce a permanent benefit in women with such deficiency. These relationships suggest that late fracture protection from earlier estrogen therapy is either confined to women with calcium deficiency, or has a non-mass basis (or both).

Original languageEnglish
Pages (from-to)67-84
Number of pages18
JournalBone and Mineral
Volume11
Issue number1
DOIs
StatePublished - 1990

Fingerprint

Postmenopause
Estrogens
Calcium
Bone
Bone and Bones
Postmenopausal Osteoporosis
Estrogen Replacement Therapy
Secondary Prevention

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Endocrinology
  • Surgery

Cite this

Estrogen-calcium interactions in the postmenopause : a quantitative description. / Heaney, Robert P.

In: Bone and Mineral, Vol. 11, No. 1, 1990, p. 67-84.

Research output: Contribution to journalArticle

@article{b7336ef3f7784dd9a510734cd29e4048,
title = "Estrogen-calcium interactions in the postmenopause: a quantitative description",
abstract = "Accumulated data describing the time course of bone loss in postmenopausal women were combined with metabolic data on estrogen-calcium interactions to produce a comprehensive, quantitative model of involutional bone loss. The model was shown to be able to mimic results of published intervention studies with considerable fidelity. Implicit in existing understanding, and made explicit by the model, are such relationships as: (1) calcium deficiency, if present in a woman, is masked during the early years of estrogen withdrawal bone loss; (2) accordingly, except in severe deficiency states, it is unlikely that calcium supplementation can confer much benefit in the immediate postmenopause; (3) however, by 5-8 years postmenopause, an underlying calcium deficiency, if present, becomes manifest, and if uncorrected will greatly augment the bone loss produced by estrogen withdrawal; (4) estrogen replacement therapy, if stopped, does not produce a sustained difference in bone mass in calcium-replete women; however, (5) estrogen, by effectively reducing the level of any calcium deficiency that may be present, does produce a permanent benefit in women with such deficiency. These relationships suggest that late fracture protection from earlier estrogen therapy is either confined to women with calcium deficiency, or has a non-mass basis (or both).",
author = "Heaney, {Robert P.}",
year = "1990",
doi = "10.1016/0169-6009(90)90016-9",
language = "English",
volume = "11",
pages = "67--84",
journal = "Bone and Mineral",
issn = "0169-6009",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Estrogen-calcium interactions in the postmenopause

T2 - a quantitative description

AU - Heaney, Robert P.

PY - 1990

Y1 - 1990

N2 - Accumulated data describing the time course of bone loss in postmenopausal women were combined with metabolic data on estrogen-calcium interactions to produce a comprehensive, quantitative model of involutional bone loss. The model was shown to be able to mimic results of published intervention studies with considerable fidelity. Implicit in existing understanding, and made explicit by the model, are such relationships as: (1) calcium deficiency, if present in a woman, is masked during the early years of estrogen withdrawal bone loss; (2) accordingly, except in severe deficiency states, it is unlikely that calcium supplementation can confer much benefit in the immediate postmenopause; (3) however, by 5-8 years postmenopause, an underlying calcium deficiency, if present, becomes manifest, and if uncorrected will greatly augment the bone loss produced by estrogen withdrawal; (4) estrogen replacement therapy, if stopped, does not produce a sustained difference in bone mass in calcium-replete women; however, (5) estrogen, by effectively reducing the level of any calcium deficiency that may be present, does produce a permanent benefit in women with such deficiency. These relationships suggest that late fracture protection from earlier estrogen therapy is either confined to women with calcium deficiency, or has a non-mass basis (or both).

AB - Accumulated data describing the time course of bone loss in postmenopausal women were combined with metabolic data on estrogen-calcium interactions to produce a comprehensive, quantitative model of involutional bone loss. The model was shown to be able to mimic results of published intervention studies with considerable fidelity. Implicit in existing understanding, and made explicit by the model, are such relationships as: (1) calcium deficiency, if present in a woman, is masked during the early years of estrogen withdrawal bone loss; (2) accordingly, except in severe deficiency states, it is unlikely that calcium supplementation can confer much benefit in the immediate postmenopause; (3) however, by 5-8 years postmenopause, an underlying calcium deficiency, if present, becomes manifest, and if uncorrected will greatly augment the bone loss produced by estrogen withdrawal; (4) estrogen replacement therapy, if stopped, does not produce a sustained difference in bone mass in calcium-replete women; however, (5) estrogen, by effectively reducing the level of any calcium deficiency that may be present, does produce a permanent benefit in women with such deficiency. These relationships suggest that late fracture protection from earlier estrogen therapy is either confined to women with calcium deficiency, or has a non-mass basis (or both).

UR - http://www.scopus.com/inward/record.url?scp=0025107350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025107350&partnerID=8YFLogxK

U2 - 10.1016/0169-6009(90)90016-9

DO - 10.1016/0169-6009(90)90016-9

M3 - Article

VL - 11

SP - 67

EP - 84

JO - Bone and Mineral

JF - Bone and Mineral

SN - 0169-6009

IS - 1

ER -